New data not so good for Boston Scientific’s Watchman anti-stroke device
Abiomed touts survival rates for its Impella right-side heart pump | TCT 2014 Roundup
Abiomed (NSDQ:ABMD) got some Wall Street love today after releasing positive outcomes from a clinical trial of its minimally invasive Impella Right Percutaneous heart pump.
Researchers reported an overall 73% 30-day survival rate in the small study of patients with right ventricular heart failure, according to data Abiomed released during the Transcatheter Cardiovascular Therapeutics conference in Washington D.C.
TCT 2014: Another trial shows no benefit for renal denervation in hypertension
TCT 2014: Medtronic’s IN.PACT Admiral beats PTA in outcomes, costs
TCT 2014: Boston Scientific’s 1-year data on Lotus TAVI device
TCT 2014 Roundup
Here’s a look at some of the news coming out of Washington at the 26th annual Transcatheter Cardiovascular Therapies conference this week:
TCT 2014: Is renal denervation dead or alive?
The efficacy of renal denervation is in doubt and should be confirmed or ruled out in treating resistant hypertension, according to an expert panel in a debate over the once high-flying technology at the Transcatheter Cardiovascular Therapeutics conference in Washington.
TCT 2014: TAVI takes center stage
St. Jude Medical hits ‘pause’ on Portico TAVI device
Stealthy mitral valve maker emerges at TCT 2014 | MassDevice.com On Call
MASSDEVICE ON CALL — Bad timing and a financial crisis nearly buried MVRx and its mitral valve repair technology forever, but the company’s founders finally revealed their progress over the weekend at the Transcatheter Cardiovascular Therapeutics conference.
